Avecho Biotechnology (ASX:AVE) Net Income From Continuing Operations : A$-3.48 Mil (TTM As of Jun. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Avecho Biotechnology Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Avecho Biotechnology's net income from continuing operations for the six months ended in Jun. 2024 was A$-2.18 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Jun. 2024 was A$-3.48 Mil.

Avecho Biotechnology Net Income From Continuing Operations Historical Data

The historical data trend for Avecho Biotechnology's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Avecho Biotechnology Net Income From Continuing Operations Chart

Avecho Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

0.85

-2.64

-3.42

-2.34

-3.44

Avecho Biotechnology Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Net Income From Continuing Operations	Get a 7-Day Free Trial															-0.78	-1.57	-2.13	-1.31	-2.18

Avecho Biotechnology Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Jun. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-3.48 Mil.

Avecho Biotechnology Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Avecho Biotechnology Ltd (ASX:AVE) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

OEZ:Germany

Address

Unit A8, 2A Westall Road, Clayton, Melbourne, VIC, AUS, 3168

Website

https://www.avecho.com.au

Avecho Biotechnology Ltd is a research-based biotechnology company engaged in the development, production, sales, and licensing of products incorporating its patented platform technology TPM, for the pharmaceutical, skincare and animal health and nutrition industries. Its segments include Production, Human Health, and other segments. The Production segment, which is the key revenue driver, manufactures and sells TPM and Vital ET for use in drug delivery and cosmetic formulations. The Human Health segment's portfolio covers the delivery of drugs through gels, injectables, and patches including the conduct of research and development activities. It focuses on the development of patches, including TPM/Oxymorphone and TPM/Oxycodone.

Avecho Biotechnology Headlines

No Headlines